

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on January 14, 2004.

Caroline Wej-Berk 45,203
Name of Attorney/Agent Registration No.
Caroline Wej-Berk
Signature of Attorney or Agent

P&G Case 8483MC

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of :
John Christopher Deak et al. : Confirmation No. Not yet assigned
Serial No. Not yet Assigned : Group Art Unit Not yet assigned
Filed January 14, 2004 : Examiner

For Process for Treating a Lipophilic Fluid

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, record is being made on the attached Form PTO/SB08 of documents which the Patent Office may wish to consider in connection with examination of the above-identified patent application. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case. As provided in §1.97(g), no representation is made or intended that a thorough art search was made. As provided in 37 C.F.R. §1.97(h), this Information Disclosure Statement does not constitute an admission of any kind, and specifically is not an admission that the documents listed on attached form PTO/SB08 are, or are considered to be, material to the patentability of the above-identified patent application, as defined in 37 C.F.R. §1.56(b).

1. ☐ **37 C.F.R. §1.97(b)(1) - U.S. Direct (use when filing IDS with nonprovisional patent application, or with Request for Continued Examination (RCE); or within 3 months of filing a nonprovisional patent application)**

This information disclosure statement, submitted under 37 C.F.R. §1.97(b)(1), is being filed with the patent application, with a Request for Continued Examination or within three months of the filing date of a national application. Therefore, no fee is believed to be due.

2. ☐ **37 C.F.R. §1.97(b)(3) - (use when filing IDS more than 3 months after filing a nonprovisional patent application, but prior to receipt of first Office Action)**

This information disclosure statement is being submitted under 37 C.F.R. §1.97(b)(3). Applicants have not received an Office Action on the merits in the present application. Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter (or a fee transmittal form) is enclosed to facilitate charging of the fee, if necessary.

3. ☐ **37 C.F.R. §1.97(b)(4) - (use when filing IDS prior to receipt of first Office Action after the filing of a Request for Continued Examination (RCE) under §1.114)**

This information disclosure statement is being submitted under 37 C.F.R. §1.97(b)(4). Applicants have not received a first Office Action after filing a Request For Continued Examination (RCE). Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter (or a fee transmittal form) is enclosed to facilitate charging of the fee, if necessary.

4. ☐ **37 C.F.R. §1.97(c) with fee payment - (use when filing IDS after receipt of first Office Action, and before receipt of Final Office Action, Notice of Allowance, or an action that otherwise closes prosecution)**

This information disclosure statement is being submitted under 37 C.F.R. §1.97(c). Applicant(s) have not received a final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in the application (e.g., *Ex parte Quayle*) as of the date of this submission. Applicant(s) elect to pay the fee set forth in 37 C.F.R. §1.17(p). Please charge the fee set forth in 37 C.F.R. §1.17(p) to Deposit Account Number 16-2480 in the name of The Procter & Gamble Company. A duplicate copy of this letter (or a fee transmittal form) is enclosed to facilitate the charging of the fee.

5. ☐ **Information to be Considered with Continued Prosecution Application (CPA) Filing (use when filing IDS with a Continued Prosecution Application (CPA) for Design Case).** This information disclosure statement is being filed with a Continued Prosecution Application (CPA) filed under 37 C.F.R. 1.53(d).

ADDITIONAL ITEMS TO BE NOTED BY THE EXAMINER:

☐ (1) (For use with applications filed prior to or on June 30, 2003.) Copies of the cited documents are enclosed.

OR

☐ (2) (For use with applications filed after June 30, 2003.) In accordance with 37 C.F.R. §1.98(a)(2), Applicants are submitting copies of foreign patent documents and non-patent literature.

OR

☒ (3) All of the cited references were previously cited by or submitted to the USPTO in prior application Case No. 8483M, U.S. Patent Application Serial No. 08/849,963, filed May 4, 2001. Applicants claim priority to said application under 35 U.S.C. §120. Accordingly, copies of previously submitted references are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d). It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case.

OR

☐ (4) Copies of all said documents, except Cite Numbers _____, were submitted and considered in parent application U.S. Patent Application Serial No. _____, filed _____. Applicant(s) claim priority to said application under 35 U.S.C. §120. Accordingly, copies of previously submitted references are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d). Copies of references not previously submitted are enclosed. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case.

☐ (5) Pursuant to 37 C.F.R. §1.98(c), a concise explanation of the relevance of each cited reference that is not in the English language is provided.

☒ (6) Applicants also respectfully request the Examiner to consider and make of record the co-pending applications listed on the attached page.

☐ Additional information is attached.

Respectfully submitted,

By Caroline Wei-Berk
 Caroline Wei-Berk
 Attorney or Agent for Applicant(s)
 Registration No. 45,203
 (513) 627-0352

Date: January 14, 2004
Customer No. 27752
 (IDS.doc) (Last Revised 10/10/03)

COPENDING APPLICATIONS

Entire copies of all co-pending applications (or the portion of the application and claims that caused it to be cited) must be sent with the IDS (see 37 CFR 1.98(a)(2)(iii))

<u>Atty. Docket No.</u>	<u>Serial Number</u>	<u>Inventor(s)</u>	<u>Filing Date</u>
8483M2	10/238,294	Deak et al.	September 10, 2002

[ones that are pending at time of this filing; others that have issued get cited on the PTO/SB08.]

Please type a plus sign (+) inside this box → [+]

PTO/SB08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031

Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<p>Substitute for form 1449A/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(use as many sheets as necessary)</p> <p>SHEET 1 of 3</p>	<p>COMPLETE IF KNOWN</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 60%;">Application Number</td> <td></td> </tr> <tr> <td>Confirmation Number</td> <td></td> </tr> <tr> <td>Filing Date</td> <td>January / 4 , 2004</td> </tr> <tr> <td>First Named Inventor</td> <td>John Christopher Deak</td> </tr> <tr> <td>Group Art Unit</td> <td></td> </tr> <tr> <td>Examiner Name</td> <td></td> </tr> <tr> <td>Attorney Docket Number</td> <td>8483MC</td> </tr> </table>	Application Number		Confirmation Number		Filing Date	January / 4 , 2004	First Named Inventor	John Christopher Deak	Group Art Unit		Examiner Name		Attorney Docket Number	8483MC
Application Number															
Confirmation Number															
Filing Date	January / 4 , 2004														
First Named Inventor	John Christopher Deak														
Group Art Unit															
Examiner Name															
Attorney Docket Number	8483MC														

U. S. PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. ¹	U.S. PATENT DOCUMENT Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		4,097,397		Mizutani et al.	06/27/1978	
		4,102,824		Mizutani et al.	07/25/1978	
		4,267,077		Niimi et al.	05/12/1981	
		4,708,807		Kemerer	11/24/1987	
		4,909,962		Clark	03/20/1990	
		4,909,962		Clark	03/20/1990	
		5,037,485		Chromecek et al.	08/06/1991	
		5,116,426		Yokohama et al.	05/26/1992	
		5,271,775		Asano et al.	12/21/1993	
		5,302,313		Asano et al.	04/12/1994	
		5,360,571		Kilgour et al.	11/01/1994	
		5,443,747		Inada et al.	08/22/1995	
		5,503,681		Inada et al.	04/02/1996	
		5,503,778		Liu et al.	04/01/1996	
		5,520,827		Danner	05/28/1996	
		5,593,507		Inada et al.	01/14/1997	
		5,597,792		Klier et al.	01/28/1997	
		5,628,883		McCormack et al.	05/13/1997	
		5,676,705		Jureller et al.	10/14/1997	
		5,683,473		Jureller et al.	11/04/1997	
		5,683,977		Jureller et al.	11/04/1997	
		5,690,750		Inada et al.	11/25/1997	
		5,705,562		Hill	01/06/1998	
		5,707,613		Hill	01/13/1998	
		5,716,456		Inada et al.	02/10/1998	
		5,722,781		Yamaguchi	03/03/1998	
		5,741,365		Inada et al.	04/21/1998	
		5,769,962		Inada et al.	06/23/1998	
		5,783,092		Brown et al.	07/21/1998	
		5,811,383		Klier et al.	09/22/1998	
		5,858,022		Romack et al.	01/12/1999	
		5,865,852		Berndt	02/02/1999	
		5,866,005		DeSimone et al.	02/02/1999	
		5,876,510		Kuemin et al.	03/02/1999	
		5,877,133		Good	03/02/1999	
		5,888,250		Hayday et al.	03/30/1999	
		5,929,012		Del Duca et al.	07/27/1999	
		5,942,007		Berndt et al.	08/24/1999	
		5,944,996		DeSimone et al.	08/31/1999	
		5,954,869		Elfersy et al.	09/21/1999	
		5,977,040		Inada et al.	11/02/1999	
		5,977,045		Murphy	11/02/1999	
		5,985,810		Inada et al.	11/16/1999	
		6,001,1233		DeYoung et al.	12/14/1999	
		6,013,683		Hill et al.	01/11/2000	
		6,042,617		Berndt	03/28/2000	
		6,042,618		Berndt et al.	03/28/2000	

		6,056,789		Berndt et al.	05/02/2000	
		6,059,845		Berndt et al.	05/09/2000	
		6,060,546		Powell et al.	05/09/2000	
		6,063,135		Berndt et al.	05/16/2000	
		6,086,635		Berndt et al.	07/11/2000	
		6,114,295		Murphy	09/05/2000	
		6,131,421		Jureller et al.	10/17/2000	
		6,136,766		Inada et al.	10/24/2000	
		6,148,644		Jureller et al.	11/21/2000	
		6,156,074		Hayday et al.	12/05/2000	
		6,177,399	B1	Mei et al.	01/23/2001	
		6,200,352	B1	Romack et al.	03/13/2001	
		6,200,393	B1	Romack et al.	03/13/2001	
		6,200,943	B1	Romack et al.	03/13/2001	
		6,204,233	B1	Smith et al.	03/20/2001	
		6,228,826	B1	DeYoung et al.	05/08/2001	
		6,242,408	B1	Elms et al.	06/05/2001	
		5,057,240		Madore et al.	10/15/1991	
		6,310,029	B1	Kilgour et al.	10/30/2001	
		6,313,079	B1	Murphy et al.	11/06/2001	
		3,395,086		Victor et al.	07/30/1968	
		3,692,467		Durr et al.	09/19/1972	
		3,839,176		McCoy et al.	10/01/1974	
		4,108,599		Coll-Palagos et al.	08/22/1978	
		4,664,754		Caputi et al.	05/12/1987	
		5,882,506		Ohsol et al.	03/16/1999	
		6,312,476	B1	Perry et al.	11/06/2001	
		6,368,359	B1	Perry et al.	04/09/2002	
		US 20020017493		Ehrensperger et al.	02/14/2002	
		US 20020038480		Deak et al.	04/04/2002	
		US 2002084715		Taylor et al.	12/12/2002	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. ¹	FOREIGN PATENT DOCUMENT		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)			
		CA	1 239 326		Kasprzak	07/19/1988	
		EP	0 479 146	B1	Kazama	12/18/1996	
		EP	1 041 189	A1	Kilgour et al.	10/04/2000	
		EP	1 092 803	A1	Murphy	04/18/2001	
		JP	00144175	A	Hirotake et al.	05/26/2000	
		JP	2000-192085		Koki et al.	07/11/2000	
		JP	00290689	A	Masahiko et al.	10/17/2000	
		JP	04323299	A			
		JP	05239766	A			
		JP	05051598	A			
		JP	08073837	A			
		JP	09143497	A			
		JP	10-017,891		Oi et al.	01/20/1998	
		JP	1098-798	A			
		JP	11-092,784		Matsumoto et al.	04/06/1999	
		JP	11-323,381		Matsumoto et al.	11/26/1999	
		JP	11-323,383		Matsumoto et al.	11/26/1999	
		JP	1188-595	A			
		JP	2166-198	A			
		JP	2202-599	A			
		JP	2222-496	A			
		JP	3046-300	A			
		JP	3063-799	A			
		WO	99/57358		Murphy	11/11/1999	
		WO	00/04221		Berndt et al.	01/27/2000	
		WO	00/04222		Berndt	01/27/2000	
		WO	00/63340		Shick et al.	10/26/2000	
		WO	01/06051	A1	Greeneearth Elec.	01/25/2001	
		WO	01/34613	A1	Greeneearth Elec.	05/17/2001	
		WO	01/34706	A1	Perry et al.	05/17/2001	
		WO	01/40567	A1	Murphy	06/07/2001	

		WO	01/27380	A1	Greenearth Cleaning	04/19/2001		
		WO	01/44256	A1	General Elec.	06/21/2001		
		WO	01/94679	A2	Procter & Gamble	12/13/2001		
		WO	02/077356	A1	General Elec.	10/03/2002		
		DE	3739711		Chemische Fabrik Dreussler	06/08/1989		
		EP	0841362		Dow Corning	05/13/1998		
		JP	61-085995		Mitsubishi	05/01/1986	(Abstract only)	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ⁶
		TRILO et al.; "CRITICAL MICELLE DENSITY FOR THE SELF-ASSEMBLY OF BLOCK COPOLYMER SURFACTANTS IN SUPERCRITICAL CARBON DIOXIDE"; Pages 416-421	
		SARBU et al.; "NON-FLUOROUS POLYMERS WITH VERY HIGH SOLUBILITY IN SUPERCRITICAL CO ₂ DOWN TO LOW PRESSURES"; Pages 165-168	

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, D.C. 20231.